Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic.
Eddy Perez-Then,Marija Miric,Han-Zhu Qian,Ying Qing Chen,Yixin Wang,Virginia Vallejo,Wanda Quezada,Melissa Flaquer,Juan Olivo,Jean Castillo,Natalia Garcia,Katherine Calderon,Scarlet Cueto,Bienvenido Veras,Miguel Russo,Indira Jimenez,Sorileydi Guzman,Luz Garabito,Evelyn Cueto,Fatima Colombo,Dominga Taveras,Dania Torres,Jeannette Baez,Jose Yunen,Ellen Koenig,Eladio Perez,Oscar Lopez,Fior Estephanie Severino Medina,Xuanyi Wang,Yiming Shao,Sten H. Vermund
DOI: https://doi.org/10.1093/ofid/ofad075
2023-01-01
Open Forum Infectious Diseases
Abstract:AbstractBackgroundA continuing nationwide vaccination campaign began in the Dominican Republic on February 16, 2021 to prevent severe consequences of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Estimates of vaccine effectiveness under real-world conditions are needed to support policy decision making and inform further vaccine selection.MethodsWe conducted a test-negative case-control study to assess the real-world effectiveness of nationwide coronavirus disease 2019 (COVID-19) vaccination program using an inactivated vaccine (CoronaVac) on preventing symptomatic SARS-CoV-2 infections and hospitalizations from August to November 2021 in the Dominican Republic. Participants were recruited from 10 hospitals in 5 provinces to estimate the effectiveness of full immunization (≥14 days after receipt of the second dose) and partial immunization (otherwise with at least 1 dose ≥14 days after receipt of the first dose).ResultsOf 1078 adult participants seeking medical care for COVID-19-related symptoms, 395 (36.6%) had positive polymerase chain reaction (PCR) tests for SARS-CoV-2; 142 (13.2%) were hospitalized during 15 days of follow up, including 91 (23%) among 395 PCR-positive and 51 (7.5%) among 683 PCR-negative participants. Full vaccination was associated with 31% lower odds of symptomatic infection (odds ratio [OR], 0.69; 95% confidence interval [CI], 0.52–0.93) and partial vaccination was associated with 49% lower odds (OR, 0.51; CI, 0.30–0.86). Among 395 PCR-positive participants, full vaccination reduced the odds of COVID-19-related hospitalization by 85% (OR, 0.15; 95% CI, 0.08–0.25) and partial vaccination reduced it by 75% (OR, 0.25; 95% CI, 0.08–0.80); full vaccination was associated with reduced use of assisted ventilation by 73% (OR, 0.27; 95% CI, 0.15–0.49).ConclusionsGiven the ancestral and delta viral variants circulating during this study period, our results suggest that the inactivated COVID-19 vaccine offered moderate protection against symptomatic SARS-CoV-2 infections and high protection against COVID-19-related hospitalizations and assisted ventilation. This is reassuring given that, as of August 2022, an estimated 2.6 billion inactivated CoronaVac vaccine doses had been administered worldwide. This vaccine will become a basis for developing multivalent vaccine against the currently circulating omicron variant.